...
首页> 外文期刊>Kidney Research and Clinical Practice >Decreased serum level and increased urinary excretion of vascular endothelial growth factor-C in patients with chronic kidney disease
【24h】

Decreased serum level and increased urinary excretion of vascular endothelial growth factor-C in patients with chronic kidney disease

机译:慢性肾脏病患者血清水平降低和血管内皮生长因子-C的尿排泄增加

获取原文
           

摘要

Background: Interstitial tonicity increases vascular endothelial growth factor-C (VEGF-C), a lymphangiogenic factor in salt-induced hypertension. Therefore, it can be assumed that changes of serum VEGF-C level may be associated with increasing blood pressure. However, there is no report about the changes of serum VEGF-C levels in patients with chronic kidney disease (CKD). The aims of this study were to investigate the changes of serum and urine VEGF-C levels in patients with CKD stage 3-4 and to evaluate the relationship between blood pressure and serum VEGF-C levels in the patients with CKD stage 5 and hemodialysis. Methods: Glomerular filtration rate (GFR) was assessed by the Modification of Diet in Renal Disease equation. Blood pressure and VEGF-C levels (serum and urine) were measured by enzyme-linked immunosorbent assay (ELISA) in nine patients with stage 3-4 CKD, 41 hemodialysis patients, and eight healthy individuals. Results: The median serum level of VEGF-C in patients with stage 3-4 CKD and stage 5 hemodialysis significantly decreased in comparison with healthy individuals. Urinary VEGF-C excretion increased in patients with stage 3-4 CKD compared with healthy control patients. For 41 hemodialysis patients, the serum level of VEGF-C in patients with stage 1 or stage 2 hypertension with hemodialysis did not significantly increase when compared with prehypertension hemodialysis patients. Conclusion: We demonstrated that circulating levels of VEGF-C were decreased in patients with CKD, and the decrease of VEGF-C in patients with stage 3-4 CKD coincided with an increase in the urinary excretion of VEGF-C.
机译:背景:间质张力增加了盐诱导的高血压中的淋巴管生成因子-血管内皮生长因子-C(VEGF-C)。因此,可以认为血清VEGF-C水平的改变可能与血压升高有关。但是,没有关于慢性肾脏病(CKD)患者血清VEGF-C水平变化的报道。这项研究的目的是调查CKD 3-4期患者的血清和尿中VEGF-C水平的变化,并评估CKD 5期与血液透析的患者血压和血清VEGF-C水平之间的关系。方法:通过饮食中肾脏疾病方程的修改来评估肾小球滤过率(GFR)。通过酶联免疫吸附测定(ELISA)测量了9例3-4 CKD患者,41例血液透析患者和8例健康个体的血压和VEGF-C水平(血清和尿液)。结果:与健康个体相比,3-4 CKD和5阶段血液透析患者的VEGF-C血清中值显着降低。 3-4 CKD期患者的尿中VEGF-C排泄与健康对照组相比有所增加。对于41例血液透析患者,与高血压前期血液透析患者相比,患有1期或2期高血压血液透析患者的VEGF-C血清水平没有显着增加。结论:我们证明CKD患者的循环中VEGF-C水平降低,而3-4 CKD患者的VEGF-C水平下降与VEGF-C的尿排泄增加相吻合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号